The expert from the Centre Hospitalier Lyon-Sud discussed the results of a phase II study of avelumab for patients with GTT who were resistant to chemotherapy.
The findings, presented at the 2020 ASCO Virtual Scientific Program, are the first to show benefit with pembrolizumab in patients with advanced colorectal cancer when used as a front-line therapy.
Data from the COVID-19 and Cancer Consortium registry, presented at the 2020 ASCO Annual Virtual Science Program, reported how the COVID-19 pandemic has impacted patients with cancer thus far.
Utilizing data from the INFORM registry, researchers were able to identify high level priority targets in pediatric patients with cancer utilizing an algorithm that matched them to targeted treatments extending their progression-free survival time and showing the feasibility of this program in a real-world setting.
Women who present with a new diagnosis of breast cancer already in stage IV should not be offered surgery and radiation for the primary breast tumor with the expectation of a survival benefit, according to results from the ECOG-ACRIN E2108 trial.
Disease progression and treatment with hydroxychloroquine and azithromycin were associated with increased all-cause 30-day mortality in patients with cancer compared to patients either in remission or with no evidence of disease, according to data presented during a 2020 ASCO Virtual Scientific Program press briefing.
Addition of Avelumab to Best Supportive Care After Firstline Chemo Improves Survival in Advanced Urothelial Cancer
Immunotherapy with avelumab improved survival when given as maintenance therapy in patients whose disease did not progress on platinum-based chemotherapy.
Front-line therapy with pembrolizumab doubled progression-free survival versus chemotherapy in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer.
The phase II study was the first trial to explore the use of immunotherapy for patients who were resistant to standard chemotherapy treatment
The use of video conference technology significantly reduced anxiety and stress among individuals who provide care for an individual with cancer and live more than 1 hour away from the patient.